DNA damage in AML cell exposed to adriamycin; correlations with clinical response to therapy.
D002478:Cells, Cultured; D003561:Cytarabine / Q000627:therapeutic use; D004260:DNA Repair / Q000187:drug effects; D004273:DNA, Neoplasm / Q000378:metabolism*; D004317:Doxorubicin / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis
D004273:DNA, Neoplasm; D003561:Cytarabine; D004317:Doxorubicin